Literature DB >> 25385946

Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.

Antonio E Pontiroli1.   

Abstract

Prevention of diabetic complications is mainly obtained through optimal control of blood glucose levels. With hypoglycemic drugs like beta-cell stimulating drugs and especially insulin, the limit to treatment is represented by hypoglycemia, a life-threatening occurrence that is dangerous itself and can induce fear of other episodes. Glucagon, injected subcutaneously (SC) or intramuscularly (IM), is the treatment of choice for severe hypoglycemia outside of the hospital setting. However, due to practical aspects such as preparation of solutions for administration and injection by untrained persons, there are obstacles to its routine use. This review focuses on the current status of alternative routes of administration of peptide hormones, and in particular the intranasal (IN) route of glucagon, as a promising approach for the treatment of severe hypoglycemia.
© 2014 Diabetes Technology Society.

Entities:  

Keywords:  diabetes; glucagon; hypoglycemia; insulin; intranasal; peptide hormones

Mesh:

Substances:

Year:  2014        PMID: 25385946      PMCID: PMC4495544          DOI: 10.1177/1932296814557518

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  32 in total

1.  Intranasal glucagon in the treatment of hypoglycaemic attacks in children: experience at a summer camp.

Authors:  G Slama; G Reach; M Cahane; C Quetin; F Villanove-Robin
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

2.  A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon.

Authors:  G Slama; C Alamowitch; N Desplanque; M Letanoux; P Zirinis
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

3.  Identification of nose-to-brain homing peptide through phage display.

Authors:  Xiao-Mei Wan; Yong-Ping Chen; Wen-Rui Xu; Wen-Jun Yang; Long-Ping Wen
Journal:  Peptides       Date:  2008-10-21       Impact factor: 3.750

4.  Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men.

Authors:  Martin Heni; Robert Wagner; Stephanie Kullmann; Ralf Veit; Haliza Mat Husin; Katarzyna Linder; Charlotte Benkendorff; Andreas Peter; Norbert Stefan; Hans-Ulrich Häring; Hubert Preissl; Andreas Fritsche
Journal:  Diabetes       Date:  2014-07-15       Impact factor: 9.461

5.  Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans.

Authors:  A Adjei; D Sundberg; J Miller; A Chun
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

6.  The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.

Authors:  W A Lee; R D Ennis; J P Longenecker; P Bengtsson
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

7.  Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Authors:  S Adami; M Passeri; S Ortolani; M Broggini; L Carratelli; I Caruso; G Gandolini; L Gnessi; M Laurenzi; A Lombardi
Journal:  Bone       Date:  1995-10       Impact factor: 4.398

8.  Glucose recovery after intranasal glucagon during hypoglycaemia in man.

Authors:  A Hvidberg; R Djurup; J Hilsted
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.

Authors:  E Stenninger; J Aman
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

10.  Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes.

Authors:  Spiros Fourlanos; Christine Perry; Shane A Gellert; Emanuela Martinuzzi; Roberto Mallone; Jeanne Butler; Peter G Colman; Leonard C Harrison
Journal:  Diabetes       Date:  2011-02-09       Impact factor: 9.461

View more
  14 in total

1.  Rapid reconstitution packages (RRPs) for stable storage and delivery of glucagon.

Authors:  Sebastian D'hers; Agustín N Abad Vazquez; Pablo Gurman; Noel M Elman
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

Review 2.  Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus.

Authors:  Samie Sabet; Michelle E Condren; Angela F Boston; Lauren C Doak; Laura J Chalmers
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

Review 3.  New Developments in Glucagon Treatment for Hypoglycemia.

Authors:  LesleAnn Hayward Story; Leah M Wilson
Journal:  Drugs       Date:  2022-08-06       Impact factor: 11.431

4.  Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.

Authors:  Johannes Pöhlmann; Beth D Mitchell; Sanjay Bajpai; Beatrice Osumili; William J Valentine
Journal:  J Diabetes Sci Technol       Date:  2019-01-30

Review 5.  Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.

Authors:  Colin P Hawkes; Diva D De Leon; Michael R Rickels
Journal:  Curr Diab Rep       Date:  2019-09-06       Impact factor: 4.810

Review 6.  Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue.

Authors:  Leah M Wilson; Jessica R Castle
Journal:  J Diabetes Sci Technol       Date:  2018-02-08

7.  The prescription rates of glucagon for hypoglycemia by pediatricians and physicians are low in Japan.

Authors:  Masaaki Matsumoto; Hiroyuki Awano; Yushi Hirota; Masashi Nagai; Ryosuke Bo; Atsuko Matsuoka; Tetsushi Hamaguchi; Takehito Takeuchi; Yasushi Nakagawa; Wataru Ogawa; Kazumoto Iijima
Journal:  Endocrine       Date:  2018-10-26       Impact factor: 3.633

8.  Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.

Authors:  Jean-François Yale; Hélène Dulude; Marc Egeth; Claude A Piché; Martin Lafontaine; Dolorès Carballo; Rebecca Margolies; Emily Dissinger; Adam R Shames; Nicole Kaplowitz; Michelle Xiaotian Zhang; Shuyu Zhang; Cristina B Guzman
Journal:  Diabetes Technol Ther       Date:  2017-05-30       Impact factor: 6.118

9.  Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.

Authors:  Elizabeth R Seaquist; Hélène Dulude; Xiaotian M Zhang; Remi Rabasa-Lhoret; George M Tsoukas; James R Conway; Stanley J Weisnagel; Gregg Gerety; Vincent C Woo; Shuyu Zhang; Dolorès Carballo; Sheetal Pradhan; Claude A Piché; Cristina B Guzman
Journal:  Diabetes Obes Metab       Date:  2018-03-22       Impact factor: 6.577

10.  Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.

Authors:  Cristina B Guzman; Helene Dulude; Claude Piché; Marianne Rufiange; Aziz A Sadoune; Emmanouil Rampakakis; Dolores Carballo; Myriam Triest; Michelle Xiaotian Zhang; Shuyu Zhang; Maryam Tafreshi; Eric Sicard
Journal:  Diabetes Obes Metab       Date:  2017-11-19       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.